• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding


Factor Products

Coagulation therapy is the foundation of CSL Behring’s broad range of therapies.

Learn More

CSL Expertise

CSL Behring is a global leader in the biotherapeutics industry.

Learn More

Expert Opinions

CSL Behring sponsors candid discussions called the Dialogue Series with key opinion leaders.

Learn More

CSL Behring prides itself on an unwavering focus on the safety and quality of our products. We are committed to producing safe and effective therapies that can improve the quality of life for people with rare and serious diseases, such as von Willebrand disease, hemophilia and other factor deficiencies.

Our Heritage of Safety

CSL Behring also takes pride in our dedication to preventing further harm in our patients. In the 1970s, it was recognized that patients — mainly children — often turned yellow after infusion of product, which is a sign of hepatitis. Professor Dr. Norbert Heimburger, a leading scientist in the field of coagulation, made it his goal to create products that would not induce additional harm to the children. Due to his efforts, the resulting virus inactivation method eliminated the transmission of hepatitis, and it was later evident that no patients were infected with HIV from our products.

International Standards for Plasma Product Safety

We are dedicated to meeting or exceeding the most stringent international standards for plasma product safety in accordance with regulatory agencies worldwide. Our dedication to collecting safe plasma and producing the highest quality products is well known in our industry and throughout our patient communities.

In addition, CSL Behring biotherapies are manufactured in state-of-the-art facilities under stringent, controlled conditions. Each step of the manufacturing process contributes to the safety of our products. Over the last 25 years, the risk of virus transmission through plasma-derived products has been virtually eliminated.

Last Updated: 11/3/2012 4:11 PM
  • E-mail
  • Print
  • Share